Everything priced, nothing gated
The landing page carries a pricing block with a figure for compounded semaglutide and one for compounded tirzepatide, each with a short list of what the drug does. No quiz, no account, no email.
It also tells a reader what kind of process this is, in four words: no phone calls, no video visit. Knowing the intake is asynchronous before starting it is a genuine courtesy.
Four numbers, and only two of them are the drug
At the top of the page, a consultation is priced. In the pricing block, the two drugs are priced. Below them, a pay-later option is priced at the smallest figure on the page.
That last one is an instalment on a credit product, offered through named financing partners at nought per cent over two years. It is a monthly repayment, not what the treatment costs, and it is the number a skimming reader will remember because it is the lowest.
The consultation figure is not the medication either. Nothing on the page says whether it recurs alongside a drug plan or is folded into it.
The footnote that swallows all four
Every figure carries an asterisk, and the asterisk resolves to the same sentence: the rate depends on plan structure and eligibility.
Nowhere does the page say what the plan structures are. So each figure is a floor conditioned on something unpublished, which is a more thorough qualification than most sellers attach and a less useful one than it appears.
Nobody's name, and a host that cannot be tested
The landing page is under six thousand characters and names no operating company. The company in this record comes from the FDA's warning letter, whose text names this seller's domain — not from anything the site says about itself.
A nonsense address on this host returns a success and lands on the same page, so nothing can be recorded as absent here because an address failed. No compounding pharmacy, prescribing clinician or state list appears in the text we can read.
It carries an FDA warning letter issued in February 2026 over false and misleading claims and misbranding. That is a disclosure and it does not move this seller's position here.
Bliv's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $116/moas low as, per month — the pricing block reads "Semaglutide ... *as low as $116 per month" and footnotes every figure on the page with "* based on plan structure and eligibility", so the plan structure that produces this rate is not published | September 2026source |
| Tirzepatide (compounded) | $199/moas low as, per month — "Tirzepatide ... *as low as $199 per month", under the same "* based on plan structure and eligibility" footnote | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 264 providers reviewed here are paid partners today; the other 260 are not. See how this works.
See Bliv's current price →Good fit if
- Readers who want prices on the first screen and will work out which figure applies to them.
- People who want an entirely asynchronous intake with no calls.
- Buyers considering financing and wanting the provider named.
Look elsewhere if
- Anyone who would read the smallest number on the page as the price.
- Buyers who want to know what plan produces the advertised rate.
- Readers who want a named company behind the sale.
- People who need the pharmacy, the prescriber or their state confirmed.
How this review was verified
- Read the homepage and the landing page it redirects to on 7 September 2026, comparing requested to effective URLs, with a nonsense path on the same host in the same run — it returned a 200, so no absence is claimed in this review.
- Separated the four figures on the page by what each one buys, and stored only the two that buy medication as prices.
- Read the asterisk footnote before recording any figure, so each price carries the condition the seller attaches to it.
- Recorded that no operating company appears on the page, and attributed the company name to the FDA letter rather than to the site.
- Screened the live FDA warning-letter datatable by entity name with a positive control returning exactly one row and a nonsense control returning none, then confirmed the letter's body names this seller's domain.